Uncategorized
Pfizer, Allergan to combine in $160 billion deal
Pfizer and Allergan announced today that their boards of directors have approved a definitive merger agreement in which Pfizer will combine with Allergan.The merger has a stock transaction currently valued at $363.63 per Allergan share, for a total value of approximately $160 billion, based on the closing price of Pfizer common stock of $32.18 on Nov. 20, according to a press release from both companies. Under the proposal, the businesses of Pfizer and Allergan will be combined under Allergan plc, which will be renamed Pfizer plc.